People
Dieser Inhalt ist noch nicht in deiner Sprache verfügbar.
People coverage tracks publicly documented executives, scientists, founders, and other industry figures whose roles help explain the botulinum toxin market. The directory starts with Allergan Aesthetics, Galderma, and Revance because those organizations connect major toxin brands, aesthetic commercialization rights, product-science claims, ownership changes, and post-acquisition market structure.
Directory
Section titled “Directory”| Name | Organization / role context |
|---|---|
| Nicole Mowad-Nassar | AbbVie / Allergan; Senior Vice President, AbbVie and President, Global Allergan Aesthetics |
| Darin J. Messina, Ph.D. | AbbVie / Allergan; Senior Vice President, Aesthetics R&D |
| Carrie Strom | Hugel; President and Global Chief Executive Officer; former Global President of Allergan Aesthetics |
| Flemming Ørnskov | Galderma; Chief Executive Officer |
| Mark Foley | Revance / Crown Laboratories; former Revance Therapeutics Chief Executive Officer; Daxxify approval-period leadership node |
| Nadeem Moiz | Revance / Crown Laboratories; Revance Chief Executive Officer |
| Thomas Hitchcock, Ph.D. | Revance / Crown Laboratories; Revance Chief Innovation Officer |
Reading Paths
Section titled “Reading Paths”| Question | Useful path |
|---|---|
| Which leaders explain AbbVie’s aesthetic-toxin business? | Start with Nicole Mowad-Nassar for the current Global Allergan Aesthetics commercial role and Darin J. Messina, Ph.D. for aesthetics R&D. |
| How did Allergan Aesthetics become a distinct AbbVie business node? | AbbVie / Allergan gives the company context, while Carrie Strom anchors the 2020 launch leadership. |
| Why does leadership movement matter for the toxin market graph? | The movement from Allergan Aesthetics to Hugel links established Botox Cosmetic commercial experience with Letybo’s global expansion context. |
| Which leader anchors Galderma’s current toxin-market strategy? | Flemming Ørnskov connects Galderma leadership to Dysport commercialization, Relfydess development, and public-company strategy. |
| How should Revance leadership be split before and after Crown’s acquisition? | Mark Foley is useful for the Daxxify approval-period Revance story, while Nadeem Moiz anchors current Revance leadership after Crown’s 2025 acquisition. |
| Who explains Revance’s product-science and innovation angle? | Thomas Hitchcock, Ph.D. links current Revance innovation leadership to Daxxify’s peptide-formulated product identity and related product-science context. |